

115TH CONGRESS 2D SESSION

H. R. 4938

To address the opioid epidemic, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

February 6, 2018

Ms. Kuster of New Hampshire introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Ways and Means, Education and the Workforce, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To address the opioid epidemic, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Respond to the Needs
- 5 in the Opioid War Act" or the "Respond NOW Act".

6 TITLE I—OPIOID EPIDEMIC

- 7 **RESPONSE FUND**
- 8 SEC. 101. OPIOID EPIDEMIC RESPONSE FUND.
- 9 (a) In General.—The Secretary of Health and
- 10 Human Services (referred to in this section as the "Sec-

- 1 retary") shall use any funds appropriated pursuant to the
- 2 authorization of appropriations under subsection (c) to
- 3 carry out the programs and activities described in sub-
- 4 section (d) to address the opioid and substance use epi-
- 5 demic. Such funds shall be in addition to any funds which
- 6 are otherwise available to carry out such programs and
- 7 activities.
- 8 (b) Opioid Epidemic Response Fund.—
- 9 (1) ESTABLISHMENT OF ACCOUNT.—There is
- 10 established in the Treasury an account, to be known
- as the Opioid Epidemic Response Fund (referred to
- in this subsection as the "Funds"), for purposes of
- funding the programs and activities described in
- subsection (d).
- 15 (2) Transfer.—For each of fiscal years 2018
- 16 through 2022, \$5,000,000,000 shall be transferred
- to the Fund from the general fund of the Treasury.
- 18 (3) Amounts Deposited.—Any amounts
- transferred under paragraph (2) shall remain un-
- available in the Fund until such amounts are appro-
- 21 priated pursuant to subsection (c).
- (c) Appropriations.—
- 23 (1) Authorization of appropriations.—For
- 24 the period of fiscal years 2018 through 2022, there
- is authorized to be appropriated from the Fund to

- the Department of Health and Human Services, for the purpose of carrying out the programs and activities described in subsection (d), an amount not to exceed the total amount transferred to the Fund under subsection (b)(2), to remain available until ex-
- 6 pended.
- 7 (2) Offsetting future appropriations.— 8 For any of fiscal years 2018 through 2022, for any 9 discretionary appropriation to the Department of 10 Health and Human Services (or any agency therein) 11 pursuant to the authorization of appropriations 12 under paragraph (1) for the purpose of carrying out 13 the programs and activities described in subsection 14 (d), the total amount of such appropriations for the 15 applicable fiscal year (not to exceed the total amount 16 remaining in the Account) shall be subtracted from 17 the estimate of discretionary budget authority and 18 the resulting outlays for any estimate under the 19 Congressional Budget and Impoundment Control 20 Act of 1974 or the Balanced Budget and Emergency 21 Deficit Control Act of 1985, and the amount trans-22 ferred to the Fund shall be reduced by the same 23 amount.
- 24 (d) Programs and Activities.—Of the total 25 amount authorized to be appropriated from the Fund to

- 1 the Department of Health and Human Services by sub-
- 2 section (c)(1), such amount shall be allocated as follows:
- 3 (1) SAMHSA.—For the Substance Abuse and
- 4 Mental Health Services Administration to carry out
- 5 programs and activities pursuant to section 102,
- 6 \$3,650,000,000 for each of fiscal years 2018
- 7 through 2022.
- 8 (2) CDC.—For the Centers for Disease Control
- 9 and Prevention to carry out programs and activities
- 10 pursuant to section 103, \$500,000,000 for each of
- fiscal years 2018 through 2022.
- 12 (3) FDA.—For the Food and Drug Adminis-
- tration to carry out programs and activities pursu-
- 14 ant to section 104, \$65,000,000 for each of fiscal
- 15 years 2018 through 2022.
- 16 (4) NIH.—For the National Institutes of
- Health to carry out programs and activities pursu-
- 18 ant to section 105, \$500,000,000 for each of fiscal
- 19 years 2018 through 2022.
- 20 (5) HRSA.—For the Health Resources and
- 21 Services Administration to carry out programs and
- activities pursuant to section 106, \$235,000,000 for
- each of fiscal years 2018 through 2022.
- 24 (6) ACF.—For the Administration for Children
- and Families to carry out programs and activities

1	pursuant to section 107, \$50,000,000 for each of
2	fiscal years 2018 through 2022.
3	(e) Accountability and Oversight.—
4	(1) Work Plan.—
5	(A) In General.—Not later than 180
6	days after the date of enactment of this Act,
7	the Secretary of Health and Human Services
8	shall submit to the Committee on Health, Edu-
9	cation, Labor, and Pensions and the Committee
10	on Appropriations of the Senate and the Com-
11	mittee on Energy and Commerce and the Com-
12	mittee on Appropriations of the House of Rep-
13	resentatives, a work plan including the proposed
14	allocation of funds appropriated pursuant to the
15	authorization of appropriations under sub-
16	section (c) for each of fiscal years 2018 through
17	2022 and the contents described in subpara-
18	graph (B).
19	(B) Contents.—The work plan submitted
20	under subparagraph (A) shall include—
21	(i) the amount of money to be obli-
22	gated or expended out of the Fund in each
23	fiscal year for each program and activity
24	described in subsection (d); and

1	(ii) a description and justification of
2	each such program and activity.
3	(2) Reports.—
4	(A) Annual reports.—Not later than
5	October 1 of each of fiscal years 2019 through
6	2023, the Secretary of Health and Human
7	Services shall submit to the Committee on
8	Health, Education, Labor, and Pensions and
9	the Committee on Appropriations of the Senate
10	and the Committee on Energy and Commerce
11	and the Committee on Appropriations of the
12	House of Representatives, a report including—
13	(i) the amount of money obligated or
14	expended out of the Fund in the prior fis-
15	cal year for each program and activity de-
16	scribed in subsection (d);
17	(ii) a description of all programs and
18	activities using funds provided pursuant to
19	the authorization of appropriations under
20	subsection (c); and
21	(iii) how the programs and activities
22	are responding to the opioid epidemic.
23	(B) Additional reports.—At the re-
24	quest of the Committee on Health, Education
25	Labor, and Pensions or the Committee on Ap-

- 1 propriations of the Senate, or the Committee on 2 Energy and Commerce or the Committee on 3 Appropriations of the House of Representatives, 4 the Commissioner shall provide an update in the form of testimony and any additional re-6 ports to the respective congressional committee 7 regarding the allocation of funding under this 8 section or the description of the programs and 9 activities undertaken with such funding.
- 10 (f) Limitations.—Notwithstanding any transfer au11 thority authorized by this Act or any appropriations Act,
 12 any funds made available pursuant to the authorization
 13 of appropriations under subsection (c) may not be used
 14 for any purpose other than the programs and activities
 15 described in subsection (d) to address the opioid and sub16 stance use epidemic.
- 17 (g) SUNSET.—This section shall expire at the end of 18 fiscal year 2027.
- 19 SEC. 102. SUBSTANCE ABUSE AND MENTAL HEALTH SERV-
- 20 ICES ADMINISTRATION.
- The entirety of the funds made available pursuant to
- 22 section 101(d)(1) shall be for carrying out subsections (c)
- 23 and (d) of section 1003 of the 21st Century Cures Act,
- 24 as amended by section 203.

1	SEC. 103. CENTERS FOR DISEASE CONTROL AND PREVEN
2	TION.
3	(a) Addressing Opioid Use Disorder.—The en-
4	tirety of the funds made available pursuant to section
5	101(d)(2) shall be for the Director of the Centers for Dis-
6	ease Control and Prevention, pursuant to applicable au-
7	thorities in the Public Health Service Act (42 U.S.C. 201
8	et seq.), to continue and expand programs of the Centers
9	for Disease Control and Prevention to address opioid use
10	disorder, including by—
11	(1) improving the timeliness and quality of data
12	on the opioid epidemic, including improvement of—
13	(A) data on fatal and nonfatal overdoses.
14	(B) syndromic surveillance;
15	(C) data on long-term sequelae (including
16	neonatal abstinence syndrome); and
17	(D) cause of death reporting related to
18	substance abuse or opioid overdose;
19	(2) expanding and strengthening evidence-based
20	prevention and education strategies;
21	(3) supporting responsible prescribing practices.
22	including through development and dissemination of
23	prescriber guidelines;
24	(4) improving access to and use of effective pre-
25	vention treatment and recovery support including

- through grants and the provision of technical assist-
- 2 ance to States and localities;
- 3 (5) strengthening partnerships with first re-4 sponders, including to protect their safety;
- 5 (6) considering the needs of vulnerable popu-6 lations;
- 7 (7) addressing infectious diseases linked to the 8 opioid crisis; and
- 9 (8) strengthening prescription drug monitoring 10 programs.
- 11 (b) Limitation.—Of the funds made available pur-
- 12 suant to section 101(d)(2) for carrying out this section,
- 13 not more than 20 percent may be used for intramural pur-
- 14 poses.

15 SEC. 104. FOOD AND DRUG ADMINISTRATION.

- The entirety of the funds made available pursuant to
- 17 section 101(d)(3) shall be for the Commissioner of Food
- 18 and Drugs, pursuant to applicable authorities in the Pub-
- 19 lic Health Service Act (42 U.S.C. 201 et seq.) or the Fed-
- 20 eral Food, Drug, and Cosmetic Act (21 U.S.C. 301 et
- 21 seq.) and other applicable law, to support widespread inno-
- 22 vation in non-opioid and non-addictive medical products
- 23 for pain treatment, access to opioid addiction treatments,
- 24 appropriate use of approved opioids, and efforts to reduce

- illicit importation of opioids. Such support may include the 2 following: 3 (1) Facilitating the development of non-opioid and non-addictive pain treatments. (2) Advancing guidance documents for sponsors 6 of non-opioid pain products. 7 (3) Developing evidence to inform the potential 8 for nonprescription overdose therapies. 9 (4) Examining expanded labeling indications for 10 medication-assisted treatment. 11 (5) Conducting public education and outreach, 12 including public workshops or public meetings, re-13 garding the benefits of medication-assisted treat-14 ment, and approved non-opioid drug and device 15 treatment options. 16 17 18
 - (6) Exploring the expansion and possible mandatory nature of prescriber education regarding pain management and appropriate opioid prescribing through authorities under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1).
- 22 (7) Examining options to limit the duration of 23 opioid prescriptions for acute pain, including 24 through packaging options.

19

20

21

1	(8) Increasing staff and infrastructure capacity
2	to inspect and analyze packages at international
3	mail facilities and pursue criminal investigations.
4	SEC. 105. NATIONAL INSTITUTES OF HEALTH.
5	The entirety of the funds made available pursuant to
6	section 101(d)(4) shall be for the Director of the National
7	Institutes of Health, pursuant to applicable authorities in
8	the Public Health Service Act (42 U.S.C. 201 et seq.),
9	to carry out activities related to—
10	(1) accelerating research for addressing the
11	opioid epidemic, including developing non-opioid
12	medications and interventions, including non-addict-
13	ive medications, to manage pain, as well as to treat
14	and to prevent substance use disorders;
15	(2) conducting and supporting research on
16	which treatments (in terms of pain management as
17	well as treating and preventing substance use dis-
18	orders) are optimal for which patients; and
19	(3) conducting and supporting research on cre-
20	ating longer-lasting or faster-acting antidotes for
21	opioid overdose, particularly in response to the prev-

alence of fentanyl and carfentanyl overdoses.

22

1	SEC. 106. HEALTH RESOURCES AND SERVICES ADMINIS
2	TRATION.
3	The entirety of the funds made available pursuant to
4	section 101(d)(5) shall be for the Administrator of the
5	Health Resources and Services Administration, pursuant
6	to applicable authorities in titles III, VII, and VIII of the
7	Public Health Service Act (42 U.S.C. 241 et seq.), to
8	carry out activities that increase the availability and ca-
9	pacity of the behavioral health workforce. Such activities
10	may include providing loan repayment assistance for sub-
11	stance abuse treatment providers.
12	SEC. 107. ADMINISTRATION FOR CHILDREN AND FAMILIES
13	Of the funds made available pursuant to section
14	101(d)(6) for each of fiscal years 2018 through 2022—
15	(1) \$25,000,000 for each such fiscal year shall
16	be for the Secretary of Health and Human Services
17	to carry out title I of the Child Abuse Prevention
18	and Treatment Act (42 U.S.C. 5101 et seq.); and
19	(2) \$25,000,000 for each such fiscal year shall
20	be for the Secretary of Health and Human Services
21	to carry out title II of such Act (42 U.S.C. 5116 et
22	seq.).

1	TITLE II—ADDITIONAL INVEST-
2	MENTS IN EXISTING PRO-
3	GRAMS TO RESPOND TO THE
4	OPIOID EPIDEMIC
5	SEC. 201. INCREASE IN FUNDING FOR REGIONAL PARTNER-
6	SHIP GRANTS.
7	Section 436 of the Social Security Act (42 U.S.C.
8	629f) is amended—
9	(1) in subsection (a), by striking
10	" $\$345,000,000$ for each of fiscal years 2012 through
11	2016" and inserting "\$385,000,000 for each of fis-
12	cal years 2018 through 2023"; and
13	(2) in subsection (b)—
14	(A) in paragraph (4)(A), by striking "2012
15	through 2016" and inserting "2018 through
16	2023''; and
17	(B) in paragraph (5), by striking
18	" $$20,000,000$ for each of fiscal years 2012
19	through 2016" and inserting "\$60,000,000 for
20	each of fiscal years 2018 through 2023".
21	SEC. 202. ACCOUNT FOR THE STATE AND TRIBAL RE-
22	SPONSE TO THE OPIOID ABUSE CRISIS.
23	Section 1003 of the 21st Century Cures Act (42
24	U.S.C. 290ee–3 note) is amended—

1	(1) in subsection $(b)(2)$, by amending subpara-
2	graph (A) to read as follows:
3	"(A) IN GENERAL.—The following
4	amounts shall be transferred to the Account
5	from the general fund of the Treasury:
6	"(i) For fiscal year 2017,
7	\$500,000,000.
8	"(ii) For each of fiscal years 2018
9	through 2022, \$3,750,000,000.";
10	(2) in subsection (b)(2), by adding at the end
11	the following:
12	"(C) Set aside.—Of the amount trans-
13	ferred pursuant to subparagraph (A) for each
14	of fiscal years 2018 through 2022, 3 percent
15	shall be set aside for Indian tribes, tribal orga-
16	nizations, and Urban Indian organizations (as
17	such terms are defined in section 4 of the In-
18	dian Health Care Improvement Act).";
19	(3) in subsection (c)(1), by striking the second
20	sentence and inserting the following: "In awarding
21	such grants and allocating funds pursuant to such
22	grants among the States, the Secretary shall account
23	for the prevalence of opioid use disorders and deaths
24	from overdose, including taking into account which
25	States are hardest hit by the opioid epidemic.":

1	(4) by redesignating subsection (f) as sub-
2	section (g); and
3	(5) by inserting after subsection (e) the fol-
4	lowing:
5	"(f) Definition.—In this section, the term 'State'
6	includes an Indian tribe, tribal organization, and Urban
7	Indian organization (as such terms are defined in section
8	4 of the Indian Health Care Improvement Act).".
9	TITLE III—EXPANDING ACCESS
10	TO TREATMENT SERVICES
11	SEC. 301. ALLOWING FOR MORE FLEXIBILITY WITH RE-
12	SPECT TO MEDICATION-ASSISTED TREAT-
13	MENT FOR OPIOID USE DISORDERS.
13 14	MENT FOR OPIOID USE DISORDERS. (a) CONFORMING APPLICABLE NUMBER.—Subclause
14	(a) Conforming Applicable Number.—Subclause
14 15	(a) Conforming Applicable Number.—Subclause (II) of section 303(g)(2)(B)(iii) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(B)(iii)) is amended to
14 15 16	(a) Conforming Applicable Number.—Subclause (II) of section 303(g)(2)(B)(iii) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(B)(iii)) is amended to
14 15 16 17	(a) Conforming Applicable Number.—Subclause (II) of section 303(g)(2)(B)(iii) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(B)(iii)) is amended to read as follows:
14 15 16 17	(a) Conforming Applicable Number.—Subclause (II) of section 303(g)(2)(B)(iii) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(B)(iii)) is amended to read as follows: "(II) The applicable number is—
14 15 16 17 18	(a) Conforming Applicable Number.—Subclause (II) of section 303(g)(2)(B)(iii) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(B)(iii)) is amended to read as follows: "(II) The applicable number is— "(aa) 100 if, not sooner
14 15 16 17 18 19 20	(a) Conforming Applicable Number.—Subclause (II) of section 303(g)(2)(B)(iii) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(B)(iii)) is amended to read as follows: "(II) The applicable number is— "(aa) 100 if, not sooner than 1 year after the date on
14 15 16 17 18 19 20	(a) Conforming Applicable Number.—Subclause (II) of section 303(g)(2)(B)(iii) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(B)(iii)) is amended to read as follows: "(II) The applicable number is— "(aa) 100 if, not sooner than 1 year after the date on which the practitioner submitted

1	and intent of the practitioner to
2	treat up to 100 patients;
3	"(bb) 100 if the practitioner
4	holds additional credentialing, as
5	defined in section 8.2 of title 42,
6	Code of Federal Regulations (or
7	successor regulations);
8	"(cc) 100 if the practitioner
9	provides medication-assisted
10	treatment (MAT) using covered
11	medications (as defined in section
12	8.2 of title 42, Code of Federal
13	Regulations (or successor regula-
14	tions)) in a qualified practice set-
15	ting (as described in section
16	8.615 of title 42, Code of Federal
17	Regulations (or successor regula-
18	tions)); or
19	"(dd) 275 if the practitioner
20	meets the requirements specified
21	in section 8.610 of title 42, Code
22	of Federal Regulations (or suc-
23	cessor regulations).".
24	(b) Eliminating Any Time Limitation for Nurse
25	Practitioners, Clinical Nurse Specialists, Cer-

- 1 TIFIED REGISTERED NURSE ANESTHETISTS, CERTIFIED
- 2 Nurse Midwives, and Physician Assistants To Be-
- 3 COME QUALIFYING PRACTITIONERS.—Section
- 4 303(g)(2)(G)(iii)(II) of the Controlled Substances Act (21
- 5 U.S.C. 823(g)(2)(G)(iii)(II)) is amended by striking "dur-
- 6 ing the period beginning on the date of enactment of the
- 7 Comprehensive Addiction and Recovery Act of 2016 and
- 8 ending on October 1, 2021" and inserting "beginning on
- 9 the date of enactment of the Comprehensive Addiction and
- 10 Recovery Act of 2016".
- 11 (c) Definition of Qualifying Other Practi-
- 12 TIONER.—Clause (iv) of section 303(g)(2)(G) of the Con-
- 13 trolled Substances Act (21 U.S.C. 823(g)(2)(G)) is
- 14 amended by striking "nurse practitioner or physician as-
- 15 sistant" each place it appears and inserting "nurse practi-
- 16 tioner, clinical nurse specialist, certified registered nurse
- 17 anesthetist, certified nurse midwife, or physician assist-
- 18 ant".
- 19 SEC. 302. COVERAGE OF METHADONE UNDER MEDICARE
- 20 PART B.
- 21 (a) COVERAGE.—Section 1861(s)(2) of the Social Se-
- 22 curity Act (42 U.S.C. 1395x(s)(2)) is amended—
- 23 (1) by striking "and" at the end of subpara-
- 24 graph (FF);

1	(2) by adding "and" at the end of subpara-
2	graph (GG); and
3	(3) by inserting after subparagraph (GG) the
4	following new subparagraph:
5	"(HH) methadone, if furnished or dis-
6	pensed (including by prescription) in an oral
7	form on or after January 1, 2018, to an indi-
8	vidual for the purpose of maintenance or detoxi-
9	fication treatment by a physician or other prac-
10	titioner who has in effect a registration or waiv-
11	er under section 303(g) of such Act (21 U.S.C.
12	823(g)) to dispense methadone for such pur-
13	pose;".
14	(b) Payment.—
15	(1) In connection with physician and sup-
16	PLIER SERVICE.—Section 1842(o)(1) of the Social
17	Security Act (42 U.S.C. 1395u(o)(1)) is amended by
18	adding at the end the following new subparagraph:
19	"(H) In the case of methadone (as de-
20	scribed in section 1861(s)(2)(HH)), the amount
21	provided under section 1847A for such drug.".
22	(2) COVERED OPD SERVICE.—Section
23	1833(t)(1)(B)(iii) of the Social Security Act (42
24	U.S.C. 1395l(t)(1)(B)(iii)) is amended by inserting

- 1 "and methadone described in paragraph (2)(HH) of 2 such section" after "section 1861(s)".
- 3 (c) BUDGET NEUTRALITY.—The Secretary of Health
- 4 and Human Services shall implement the amendments
- 5 made by this section in a manner such that—
- 6 (1) estimated expenditures under the physician 7 fee schedule under section 1848 of the Social Secu-8 rity Act (42 U.S.C. 1395w-4) with application of 9 such amendments are equal to estimated expendi-10 tures under such schedule without application of 11 such amendments; and
 - (2) estimated expenditures under the prospective payment system under section 1833(t) of the Social Security Act (42 U.S.C. 1395l(t)) with application of such amendments made by this section are equal to estimated expenditures under such system without application of such amendments.

 \bigcirc

12

13

14

15

16

17